Y Intercept Hong Kong Ltd Invests $304,000 in TG Therapeutics, Inc. $TGTX

Y Intercept Hong Kong Ltd acquired a new stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 9,165 shares of the biopharmaceutical company’s stock, valued at approximately $304,000.

Other large investors have also modified their holdings of the company. Royal Bank of Canada raised its stake in shares of TG Therapeutics by 16.4% in the 1st quarter. Royal Bank of Canada now owns 75,692 shares of the biopharmaceutical company’s stock valued at $2,985,000 after buying an additional 10,660 shares in the last quarter. NewEdge Advisors LLC boosted its position in shares of TG Therapeutics by 9.6% during the 1st quarter. NewEdge Advisors LLC now owns 7,593 shares of the biopharmaceutical company’s stock valued at $299,000 after acquiring an additional 665 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in TG Therapeutics by 21.9% in the first quarter. Goldman Sachs Group Inc. now owns 1,919,416 shares of the biopharmaceutical company’s stock valued at $75,683,000 after acquiring an additional 345,059 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in TG Therapeutics by 5.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 287,059 shares of the biopharmaceutical company’s stock valued at $11,319,000 after acquiring an additional 14,689 shares during the period. Finally, EverSource Wealth Advisors LLC raised its position in TG Therapeutics by 86.3% in the second quarter. EverSource Wealth Advisors LLC now owns 1,237 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 573 shares in the last quarter. 58.58% of the stock is currently owned by institutional investors and hedge funds.

TG Therapeutics News Roundup

Here are the key news stories impacting TG Therapeutics this week:

• Positive Sentiment: HC Wainwright kept a Buy rating on TG Therapeutics and maintained a $77 price target, reinforcing a constructive outlook for the shares. TG Therapeutics (TGTX) Gets a Buy from H.C. Wainwright
• Positive Sentiment: Analysts raised long-term earnings estimates for FY2028, FY2029, and FY2030, indicating improving confidence in TG Therapeutics’ multi-year growth prospects.
• Neutral Sentiment: HC Wainwright lowered several near-term EPS estimates for 2026 and FY2027, which may temper enthusiasm in the short run but does not change the bullish rating.
• Negative Sentiment: Reduced earnings forecasts for Q2, Q3, Q4 2026 and FY2026 suggest the market may be pricing in some execution risk or slower-than-previously-expected profitability.

TG Therapeutics Price Performance

NASDAQ:TGTX opened at $56.41 on Thursday. The firm has a market cap of $8.64 billion, a PE ratio of 19.72, a price-to-earnings-growth ratio of 1.41 and a beta of 1.60. TG Therapeutics, Inc. has a 12 month low of $25.28 and a 12 month high of $59.30. The company has a quick ratio of 5.12, a current ratio of 5.81 and a debt-to-equity ratio of 1.28. The company’s 50-day moving average price is $47.27 and its two-hundred day moving average price is $36.86.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.23 by ($0.11). TG Therapeutics had a return on equity of 88.73% and a net margin of 65.95%.The firm had revenue of $204.92 million for the quarter, compared to the consensus estimate of $200.33 million. During the same period in the prior year, the company posted $0.03 earnings per share. TG Therapeutics’s quarterly revenue was up 69.5% compared to the same quarter last year. On average, equities analysts anticipate that TG Therapeutics, Inc. will post 1.42 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have commented on TGTX. Weiss Ratings upgraded shares of TG Therapeutics from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, May 1st. Bank of America increased their target price on TG Therapeutics from $17.00 to $20.00 and gave the stock an “underperform” rating in a report on Tuesday, July 7th. HC Wainwright raised their target price on TG Therapeutics from $70.00 to $77.00 and gave the stock a “buy” rating in a research report on Monday. Zacks Research raised TG Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, June 1st. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $83.00 price target on shares of TG Therapeutics in a research report on Monday, June 22nd. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, TG Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $53.33.

About TG Therapeutics

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.